Published in Eur J Cancer on June 27, 2006
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies | NCT00703625
mTOR signaling and drug development in cancer. Nat Rev Clin Oncol (2010) 2.77
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol (2010) 1.27
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer (2013) 1.05
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest New Drugs (2013) 0.95
New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging (2014) 0.95
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci (2014) 0.90
Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol (2010) 0.90
Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol (2013) 0.86
Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. Oncologist (2015) 0.86
What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents. Emerg Radiol (2012) 0.82
The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) (2012) 0.81
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. Ther Adv Urol (2015) 0.79
Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer (2016) 0.79
Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev (2011) 0.78
Sirolimus-induced bronchiolitis obliterans organizing pneumonia in a kidney transplant recipient; a case report and review of literature. J Nephropathol (2014) 0.77
Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. Curr Oncol (2009) 0.76
KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice. Mol Neurobiol (2016) 0.76
Reactivation of tuberculosis during temsirolimus therapy. Invest New Drugs (2010) 0.75
Impairments that influence physical function among survivors of childhood cancer. Children (Basel) (2015) 0.75
Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics (2017) 0.75
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. Oncologist (2017) 0.75
Everolimus-related organizing pneumonia: a report establishing causality. Invest New Drugs (2010) 0.75
Retracted High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol (1995) 6.65
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens (2001) 2.95
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23
Impact of the media and the internet on oncology: survey of cancer patients and oncologists in Canada. J Clin Oncol (2001) 2.23
Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy? Clin Oncol (R Coll Radiol) (2004) 2.12
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol (2007) 2.03
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol (2008) 1.67
Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med (1999) 1.63
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer (2006) 1.54
Direct medical costs attributable to osteoporotic fractures. Osteoporos Int (2002) 1.44
Nomenclature for synthetic gene delivery systems. Hum Gene Ther (1997) 1.44
Management of stage II seminoma. J Clin Oncol (1998) 1.43
HLA-DP based resistance to Hodgkin's disease. Lancet (1989) 1.42
Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol (1995) 1.41
Smoking and anaesthesia. Anaesthesia (1987) 1.28
Overnight shift from obstructive to central apneas in patients with heart failure: role of PCO2 and circulatory delay. Circulation (2001) 1.24
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer (2006) 1.24
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol (2005) 1.23
Risks of elective cardiac surgery: what do patients want to know? Heart (2001) 1.22
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol (2005) 1.21
Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J (2000) 1.12
Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat (1991) 1.11
Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol (2001) 1.11
Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res (2001) 1.09
Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer (1994) 1.09
Pituitary apoplexy following isosorbide administration. J Neurol Neurosurg Psychiatry (1987) 1.07
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Ann Oncol (1996) 1.07
An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. Curr Med Chem Anticancer Agents (2004) 1.07
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol (2013) 1.06
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J Clin Oncol (2000) 1.06
Sustained effects of gene-activated matrices after CNS injury. Mol Cell Neurosci (2001) 1.05
Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol (1979) 1.04
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol (2010) 1.03
Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Ann Oncol (2009) 1.03
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1999) 1.03
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol (2011) 1.01
Sinonasal angiosarcoma with marrow involvement at presentation mimicking malignant lymphoma: cytogenetic analysis using multiple techniques. Cancer Genet Cytogenet (2001) 1.01
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol (2012) 1.00
T- and T/natural killer-cell lymphomas of the salivary gland: a clinicopathologic, immunohistochemical and molecular study of six cases. Hum Pathol (1997) 1.00
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer (1996) 0.99
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol (2004) 0.99
Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Int J Gynecol Cancer (2007) 0.98
Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis (2000) 0.98
Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial. Int J Radiat Oncol Biol Phys (1989) 0.98
The decision to accept treatment for osteoporosis following hip fracture: exploring the woman's perspective using a stage-of-change model. Osteoporos Int (2002) 0.97
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol (2011) 0.96
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer (2013) 0.95
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecol Oncol (2009) 0.95
Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol (2007) 0.95
State-of-the-art management of nasopharyngeal carcinoma: current and future directions. Br J Cancer (2005) 0.95
A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol (1995) 0.95
A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) (2007) 0.94
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer (2013) 0.94
Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol (2014) 0.93
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Clin Cancer Res (2000) 0.93
Treatment of epithelial carcinoma of the ovary: operation, irradiation, and chemotherapy. Am J Obstet Gynecol (1977) 0.92
Is placental alkaline phosphatase (PLAP) a useful marker for seminoma? Eur J Cancer (1990) 0.91
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol (2002) 0.90
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol (2007) 0.90
Radiation therapy of localized non-Hodgkin's lymphoma. Cancer Treat Rep (1977) 0.89
Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. Ann Oncol (2012) 0.89
Post-operative radiochemotherapy for gastric cancer: adoption and adaptation. Clin Oncol (R Coll Radiol) (2005) 0.88
Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. Clin Oncol (R Coll Radiol) (2005) 0.88
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J Thorac Oncol (2012) 0.87
A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol (2000) 0.87
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol (2010) 0.87
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol (2011) 0.87
The importance of age and obesity on the relation between diabetes and left ventricular mass. J Am Coll Cardiol (2001) 0.87
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer (2011) 0.87
Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy. Gynecol Oncol (2010) 0.87
Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol (1997) 0.86
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Br J Cancer (2012) 0.86
Fertility risk discussions in young patients diagnosed with colorectal cancer. Curr Oncol (2012) 0.86
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. Contemp Clin Trials (2008) 0.86
A comparison of patient knowledge of clinical trials and trialist priorities. Curr Oncol (2013) 0.86
Strengths and limitations of molecular subtyping in a community outbreak of Legionnaires' disease. Epidemiol Infect (2000) 0.86
NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol (2000) 0.85
Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant (2005) 0.85
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol (1999) 0.85
High-dose methotrexate for gestational trophoblastic disease. Gynecol Oncol (1994) 0.84
Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells. Gene Ther (2006) 0.84
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol (2007) 0.84